Treating Patients With Breast Cancer After Progression on Endocrine Therapy

Sara Hurvitz, MD, discusses recent updates for selective estrogen receptor degraders in the treatment of patients with metastatic breast cancer and how it has impacted clinical decisions.

Sara Hurvitz, MD, discusses updates of the EMERALD trial investigating elacstrant vs the standard of care, including the subgroups of patients who received prior CDK4/6 inhibition for 6, 12, or 18 months.

During a Targeted Oncology™ Case-Based Roundtable™ event, Claudine Isaacs, MD, discussed with participants their reactions to the data from the phase 3 EMERALD study of elacestrant for patients with metastatic ER+ breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Claudine Isaacs, MD, discussed with participants what they see as the role of elacestrant for patients with ER+, HER2-negative breast cancer. This is the second of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Mark Pegram, MD, and participants discussed their next steps for a patient with breast cancer after progression on aromatase inhibitor plus palbociclib, including repeat biomarker testing.

During a Targeted Oncology™ Case-Based Roundtable™ event, Mark Pegram, MD, and participants discussed the use of elacestrant for patients who have received prior endocrine therapy for ER-positive, HER2-negative breast cancer. This is the second of 2 articles based on this event.

In this first part of a 2-article series, Joyce O’Shaughnessy, MD, recent updates to treatment and testing guidelines for patients with advanced breast cancer whose disease harbors an ESR1 mutation.

In the second article of a 2-part series, Joyce O’Shaughnessy, MD, discusses the most recent findings from the phase 3 EMERALD study for patients with hormone receptor–positive metastatic breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Reshma L. Mahtani, DO, and participants discussed switching CDK4/6 inhibitors and continuing use beyond progression in patients with metastatic breast cancer. This is the first of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Reshma L. Mahtani, DO, discussed with other physicians their experience with elacestrant in patients with estrogen receptor–positive, HER2-negative breast cancer. This is the second article based on this event.

In the first article of a 2-part series, Hope S. Rugo, MD, FASCO, discusses how the use of circulating tumor DNA can aid in allowing next generation sequencing to better identify targets for patients with hormone receptor positive metastatic breast cancer.